


PHARMACEUTICAL 2022

Chemomab Therapeutics Ltd. Rank 37 of 466







RealRate

PHARMACEUTICAL 2022

Chemomab Therapeutics Ltd. Rank 37 of 466

The relative strengths and weaknesses of Chemomab Therapeutics Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Chemomab Therapeutics Ltd. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 60% points. The greatest weakness of Chemomab Therapeutics Ltd. is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 277%, being 199% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	62,688
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,650
Liabilities, Non-Current	237
Other Assets	1,308
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-111
Other Revenues	0
Property and Equipment	357
Research and Development	6,334
Selling, General and Administrative Expense	6,033

Output Variable	Value in 1000 USD
Assets	64,353
Liabilities	2,887
Expenses	12,367
Revenues	0
Stockholders Equity	61,466
Net Income	-12,478
Comprehensive Net Income	-12,478
Economic Capital Ratio	277%

